RE:RE:RE:RE:RE:RE:CXR was not bought out becauseI personally think the authors of the original wall street journal article got it wrong. True that there will be a strong movement towards LOE drugs by health providers and public payers looking to save money as their premiums and tax bases shrink and the need for healtcare increases. Not true that Valeant practices are echoed by ethical pharma companies. Go ahead and have grater scrutiny, concordia already pass the grade. The govt and health provider budget silos will be asked to squeeze out more for less, resulting in bidding for access contracts. Companies that can step up in diverse therapeutic areas, offer a package deal on diverse drugs as one supplier, and have the economomies of scale to compete will do well.